Long-term follow-up results of imatinib mesylate therapy in chronic phase chronic myeloid leukemia (CML-CP) after interferon alpha (IFN) failure

被引：0
|
作者：
Shan, J. [1 ]
O'Brien, S. M. [1 ]
Garcia-Manero, G. [1 ]
Faderl, S. [1 ]
Ravandi, F. [1 ]
Jabbour, E. [1 ]
Cortes, J. E. [1 ]
Kantarjian, H. [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.6550
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6550
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Very Long-Term Follow-up Results of Imatinib Mesylate Therapy in Chronic Phase Chronic Myeloid Leukemia After Failure of Interferon Alpha Therapy
    Alattar, Mona Lisa
    Cortes, Jorge E.
    O'Brien, Susan
    Garcia-Manero, Guillermo
    Faderl, Stefan
    Ravandi, Farhad
    Jabbour, Elias
    Shan, Jianqin
    Kantarjian, Hagop M.
    BLOOD, 2011, 118 (21) : 1182 - 1182
  • [2] Very long-term follow-up results of imatinib mesylate therapy in chronic phase chronic myeloid leukemia after failure of interferon alpha therapy
    Kantarjian, Hagop
    O'Brien, Susan
    Garcia-Manero, Guillermo
    Faderl, Stefan
    Ravandi, Farhad
    Jabbour, Elias
    Shan, Jianqin
    Cortes, Jorge
    CANCER, 2012, 118 (12) : 3116 - 3122
  • [3] Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous leukemia (CML-CP) after IFN-α failure and in late CML-CP, comparison with historical controls
    Kantarjian, H
    O'Brien, S
    Cortes, J
    Giles, F
    Shan, JQ
    Rios, MB
    Faderl, S
    Verstovsek, S
    Garcia-Manero, G
    Wierda, W
    Kornblau, S
    Ferrajoli, A
    Keating, M
    Talpaz, M
    CLINICAL CANCER RESEARCH, 2004, 10 (01) : 68 - 75
  • [4] Long term follow-up of frontline dasatinib in patients (pts) with early chronic phase chronic myeloid leukemia (CML-CP).
    Maiti, Abhishek
    Kantarjian, Hagop M.
    Patel, Keyur
    Borthakur, Gautam
    Ravandi, Farhad
    Verstovsek, Srdan
    Ferrajoli, Alessandra
    Estrov, Zeev
    Kadia, Tapan M.
    Skinner, Jeffrey A.
    Poku, Rebecca A.
    Dellasala, Sara
    Luthra, Rajyalakshmi
    Jabbour, Elias
    Cortes, Jorge E.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [5] Long-Term Follow-up of Chronic Phase Chronic Myeloid Leukemia Patients Who Failed Interferon Alpha and Switched to Imatinib
    Breccia, Massimo
    Loglisci, Giuseppina
    Salaroli, Adriano
    Serrao, Alessandra
    Zacheo, Irene
    Latagliata, Roberto
    Alimena, Giuliana
    BLOOD, 2012, 120 (21)
  • [6] Long-term follow-up results of alpha-interferon (alpha-IFN)-based regimens in patients with late chronic phase chronic myelogenous leukemia (CP-CML).
    Sacchi, S
    Kantarjian, H
    OBrien, S
    Keating, M
    Freireich, E
    Talpaz, M
    BLOOD, 1996, 88 (10) : 3531 - 3531
  • [7] Results of imatinib mesylate (STI571) in Philadelphia chromosome positive chronic myelogenous leukemia in chronic phase (Ph plus CML-CP) post interferon alpha (IFN) failure.
    Kantarjian, HM
    Cortes, J
    O'Brien, S
    Faderl, S
    Thomas, D
    Giles, F
    Garcia-Manero, G
    Albitar, M
    Andreeff, M
    Kornblau, SM
    Rios, MB
    Shan, J
    Beran, M
    Koller, CA
    Resta, D
    Capdeville, R
    Estey, EH
    Keating, MJ
    Freireich, EJ
    Talpaz, M
    BLOOD, 2001, 98 (11) : 260B - 260B
  • [8] Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-α treatment
    Hochhaus, Andreas
    Druker, Brian
    Sawyers, Charles
    Guilhot, Francois
    Schiffer, Charles A.
    Cortes, Jorge
    Niederwieser, Dietger W.
    Gambacorti, Carlo
    Stone, Richard M.
    Goldman, John
    Fischer, Thomas
    O'Brien, Stephen G.
    Reiffers, Jose J.
    Mone, Manisha
    Krahnke, Tillmann
    Talpaz, Moshe
    Kantarjian, Hagop M.
    BLOOD, 2008, 111 (03) : 1039 - 1043
  • [9] Nilotinib in chronic myeloid leukemia patients in chronic phase (CML-CP) with imatinib (IM) resistance or intolerance: Longer follow-up results of a phase II study
    Kantarjian, H.
    Giles, F.
    Bhalla, K.
    Pinilla, J.
    Larson, R. A.
    Gattermann, N.
    Ottmann, O. G.
    Gallagher, N. J.
    Baccarani, M.
    leCoutre, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [10] DASATINIB 100 MG ONCE DAILY FOR CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CML-CP) FOLLOWING IMATINIB FAILURE: LONG-TERM FOLLOW-UP FROM STUDY CA180-034
    Hochhaus, A.
    Kim, D. W.
    Kantarjian, H. M.
    Rousselot, P.
    Dorlhiac-Llacer, P.
    Milone, J.
    Shah, N. P.
    Matloub, Y.
    Lambert, A.
    Stone, R. M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 441 - 441
12345